A single institutional clinical outcome for stages III and IV ovarian cancer patients treated with dose‐dense TC therapy in the frontline or first platinum‐sensitive relapse setting
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Obstetrics and Gynaecology Research"
DOI: 10.1111/jog.16018
Abstract: Dose‐dense paclitaxel /carboplatin (ddTC) therapy was shown to be more effective against ovarian cancer than conventional tri‐weekly TC in the JGOG3016 study. However, two phase III studies performed after JGOG3016 did not show the same… read more here.
Keywords: cancer; ovarian cancer; frontline first; dose dense ... See more keywords